Literature DB >> 12244187

Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

Klaus Heckelsmiller1, Katharina Rall, Sebastian Beck, Angelika Schlamp, Julia Seiderer, Bernd Jahrsdörfer, Anne Krug, Simon Rothenfusser, Stefan Endres, Gunther Hartmann.   

Abstract

The immune system of vertebrates is able to detect bacterial DNA based on the presence of unmethylated CpG motifs. We examined the therapeutic potential of oligodeoxynucleotides with CpG motifs (CpG ODN) in a colon carcinoma model in BALB/c mice. Tumors were induced by s.c. injection of syngeneic C26 cells or Renca kidney cancer cells as a control. Injection of CpG ODN alone or in combination with irradiated tumor cells did not protect mice against subsequent tumor challenge. In contrast, weekly injections of CpG ODN into the margin of already established tumors resulted in regression of tumors and complete cure of mice. The injection site was critical, since injection of CpG ODN at distant sites was not effective. Mice with two bilateral C26 tumors rejected both tumors upon peritumoral injection of one tumor, indicating the development of a systemic immune response. The tumor specificity of the immune response was demonstrated in mice bearing a C26 tumor and a Renca tumor at the same time. Mice that rejected a tumor upon peritumoral CpG treatment remained tumor free and were protected against rechallenge with the same tumor cells, but not with the other tumor, demonstrating long term memory. Tumor-specific CD8 T cells as well as innate effector cells contributed to the antitumor activity of treatment. In conclusion, peritumoral CpG ODN monotherapy elicits a strong CD8 T cell response and innate effector mechanisms that seem to act in concert to overcome unresponsiveness of the immune system toward a growing tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244187     DOI: 10.4049/jimmunol.169.7.3892

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo.

Authors:  Sven Klaschik; Debra Tross; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2009-01-29       Impact factor: 4.962

Review 3.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

Review 4.  Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.

Authors:  Oana Draghiciu; Joyce Lubbers; Hans W Nijman; Toos Daemen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 5.  Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Authors:  Jason R Baird; Arta M Monjazeb; Omid Shah; Heather McGee; William J Murphy; Marka R Crittenden; Michael J Gough
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-19       Impact factor: 7.038

6.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

7.  CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.

Authors:  Xian-Song Wang; Zhen Sheng; You-Bing Ruan; Yang Guang; Mu-Lan Yang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

8.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

9.  CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Authors:  Marie Jordan; David J Waxman
Journal:  Cancer Lett       Date:  2015-12-03       Impact factor: 8.679

10.  Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Authors:  Stefan Nierkens; Martijn H den Brok; Thijs Roelofsen; Jori A L Wagenaars; Carl G Figdor; Theo J Ruers; Gosse J Adema
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.